ClinicalTrials.gg
CompletedNCT05635084Updated Nov 18, 2024

A First-in-human Study of YN001 in Healthy Volunteers

A Phase 1 interventional study of YN001 and Placebo for YN001 in Cardiovascular Diseases, sponsored by Beijing Inno Medicine Co., Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by Beijing Inno Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This will be a single center, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study in healthy adult subjects.

Read the detailed description

A total of approximately 73 to 89 healthy male and female subjects will be enrolled into this study, it includes two parts:

Part A is single ascending dose stage, approximately 49 to 65 healthy subjects will be enrolled into about eight to ten cohorts. Subjects who meet eligibility criteria at screening will be admitted for baseline evaluations (Day -1). All baseline safety evaluation results must be available prior to dosing. The doses will be progressively escalated, with a sentinel dosing strategy employed for all cohorts.

Part B is multiple ascending dose stage, approximately 24 healthy subjects will be enrolled into about three cohorts. Subjects who meet eligibility criteria at screening will be admitted for baseline evaluations (Day -1). All baseline safety evaluation results must be available prior to dosing. The cohort M1 will be initiated by decision of SRC(safety review committee), then the doses will be progressively escalated.

02

Conditions studied

  • Cardiovascular Diseases
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 64 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Beijing Inno Medicine Co., Ltd. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained before any assessment is performed.
  2. Healthy male and female adults aged from 18 to 55 Years of age included, and in good health as determined by past medical history, physical examination, and vital signs, , and laboratory tests at screening.
  3. At screening, and baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the subject has rested for at least three (3) minutes.
  4. Weigh at least 50 kg, and have a (BMI) within the rage of 18-32 kg/m2.
  5. Willing and able to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

Subjects fulfilling any of the following criteria are not eligible for inclusion in this study.

  1. Receiving an agent at the time of enrollment, or within 30 days or 5 half-lifes of enrollment, whichever is longer prior to study drug administration.
  2. Use of any prescription drugs, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, COVID-19 vaccine, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing. If needed, (i.e., an incidental and limited need of maximum 2 g per day, no more than 3 consecutive days within 2 weeks prior to dosing) paracetamol is acceptable, but must be documented in the Concomitant medications page of the CRF.
  3. Fasting triglyceride concentration >2.8 mmol/L.
  4. A history of abnormalities, or any of the following ECG abnormalities at Screening or Baseline:

    • PR > 220 msec
    • QRS complex > 120 msec
    • > 450 msec (males)
    • QTcB > 470 msec (females)
  5. Pregnant or nursing (lactating) women.
  6. Women of , defined as all women physiologically capable of becoming pregnant UNLESS the subject agrees to comply with highly effective, double barrier for the entire duration of the study and for a period of 30 days after the dose of study drug. Fertile males, defined as all males physiologically capable of conceiving offspring UNLESS the subject agrees to comply with highly effective, double barrier contraception for the entire duration of the study and for a period of 30 days after the dose of study drug.
  7. Smokers (use of tobacco products in the previous 1 month). Urine cotinine levels will be measured during screening and at baseline for all subjects. Smokers will be defined as any subject who reports tobacco use and/or who has a urine cotinine ≥ 500 ng/mL. For light smokers to pass the cotinine test, smoking should be stopped at least 24 hours prior to reporting to the center (i.e., Day -2, early morning). Smoking will not be allowed during the study.
  8. History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays for alcohol, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates conducted during screening and/or baseline. Any THC-containing products should not be used at least 7 days prior to screening, and participant needs to abstain any THC-containing products during the trial. Alcohol abuse was defined as consumption of 14 or more standard drinks per week.
  9. A positive surface antigen (HBsAg), or positive virus (HCV) or (HIV) test result.
  10. A positive COVID-19 test result.
  11. History of myopathy/myalgia, or susceptible to myopathy/rhabdomyolysis (e.g., hypothyroidism, family history of hereditary myopathy, previous muscle toxicity with HMG-CoA reductase inhibitors or fibrates).
  12. Multiple drug allergies, or history of allergic reactions to rosuvastatin or any components of the study drug.
  13. Donation or loss of more than 400 mL of blood within 3 months prior to study drug administration.
  14. Plasma donation (> 100 ml) within 60 days prior to first dosing.
  15. levels below 12.0 g/dl at screening.
  16. Recent (within the last 3 years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc.).
  17. Recent (within the last 3 years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and , treated or not treated), or cardiac dysfunction or myocardial infarction.
  18. History of significant food allergies (e.g. anaphylactic reactions). Mild (non-anaphylactic, ) food allergies such as lactose intolerance/glucose intolerance are permitted.
  19. Any surgical or medical condition which might significantly alter the distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. The Investigator should make this determination in consideration of the subject's medical history and/or clinical or laboratory evidence of any of the following:

    • Inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding in the last 6 months;
    • Pancreatic injury or pancreatitis in the last 6 months;
    • Liver disease or liver injury as indicated by abnormal liver function tests such as (AST), SGPT (ALT), γ-GT, alkaline phosphatase, or serum . The Investigator should be guided by the following criteria:
    • Any single parameter of ALT, AST, γ-GT, alkaline phosphatase, or serum bilirubin must not exceed 1.5 x (ULN).
    • Any elevation above ULN of more than one parameter of ALT, AST, γ-GT, alkaline phosphatase, or serum bilirubin excludes a subject from participation in the study.

    If necessary, laboratory testing may be repeated on one occasion (as soon as possible) prior to randomization, to rule out any laboratory error.

    • History or presence of impaired renal function as indicated by clinically significantly abnormal creatinine or BUN and/or urea values, or abnormal urinary constituents (e.g., albuminuria).
    • Evidence of urinary obstruction or difficulty in voiding at screening.
  20. Significant illness resolved within two (2) weeks prior to initial dosing.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    YN001

    YN001 (with a strength of 5 mL:10 mg). Subjects will be administered 250 to 500 mL of YN001 diluted in 5% dextrose injection up to 120 min(which allows a +/-5 min infusion window) intravenous infusion.

    Drug: YN001

  • Placebo comparator
    Matching placebo for YN001

    Matching placebo for YN001 is 5% dextrose injection. Subjects will be administered 250 to 500mL of 5% dextrose injection up to 120 min (which allows a +/-5 min infusion window) intravenous infusion.

    Drug: Placebo for YN001

Interventions

  • DrugYN001

    Dose ranges from 2-90mg

  • DrugPlacebo for YN001

    5% dextrose injection to mimic the YN001

    Also known as: YN001

06

What researchers measure

Primary outcomes

  1. The safety and tolerability of intravenously administered YN001 in healthy subjects.

    To evaluate the incidence of Adverse Events as Assessed by CTCAE v5.0, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities, Clinically Significant Physical Examination Abnormalities and Infusion Reaction.

    Time frame: Up to 15 days of last dose

Secondary outcomes

  1. Area under the plasma concentration-time curve from time 0 to the collection time point of the last measurable concentration (AUC0-t)

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

  2. Area under the plasma concentration-time curve to infinity(AUCinf)

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

  3. Maximum plasma concentration(Cmax)

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

  4. Time of maximum concentration (Tmax)

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

  5. Clearance(CL)

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

  6. Elimination half-life (t1/2)

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

  7. Volume of distribution estimates (Vdss)

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

  8. Immunogenicity

    To evaluate the immunogenicity YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

07

Study locations

1 site
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Aug 2024, 19 months.

Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 19 months is above that.

Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Dec 2, 2022
StartActual
Dec 16, 2022
Primary completionActual
Aug 9, 2024
CompletionActual
Aug 9, 2024
Last update
Nov 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05635084
Lead sponsor
Beijing Inno Medicine Co., Ltd.
Responsible party
Sponsor
First posted
Dec 2, 2022
Start date
Dec 16, 2022
Primary completion
Aug 9, 2024
Completion
Aug 9, 2024
Last update
Nov 18, 2024

Study contacts

Ofer Gonen, Ph.D
principal investigator · Nucleus Network Pty Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YN001

Start the discussion